[{"id":"5d7622ad-719f-47cd-90a0-999fd39d85cf","acronym":"FLYSYN-101","url":"https://clinicaltrials.gov/study/NCT02789254","created_at":"2021-01-18T13:41:02.192Z","updated_at":"2024-07-02T16:35:24.982Z","phase":"Phase 1/2","brief_title":"FLYSYN in MRD Positive AML","source_id_and_acronym":"NCT02789254 - FLYSYN-101","lead_sponsor":"Synimmune GmbH","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 wild-type • FLT3 expression","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 wild-type • FLT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VX-A901"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/07/2017","start_date":" 02/07/2017","primary_txt":" Primary completion: 09/27/2021","primary_completion_date":" 09/27/2021","study_txt":" Completion: 09/27/2021","study_completion_date":" 09/27/2021","last_update_posted":"2023-12-28"}]